



production in a SA-dependent manner.





# **Development of Logic Gated CAR-NK cells for the treatment of solid tumors**

## Senti Biosciences, Inc. South San Francisco, CA

### Alba Gonzalez-Junca, Assen Roguev, Brian Garrison, Nicholas Frankel, Derrick Lee, Marcus Gainer, Alyssa Mullenix, Russell Gordley, Kathryn Loving, Jenny Chien, Gary Lee

- express the Safety Antigen VSIG2. SENTI-401 can address an unmet need in
- CRC, by targeting a widely expressed tumorassociated antigen CEA, while protecting antigen-expressing healthy cells.
- The NOT gate gene circuit can reduce targetmediated cytotoxicity in a Safety Antigen dependent manner, enabling the possibility to target numerous tumor associated antigens that are also expressed in healthy tissues.

Senti Bio is developing a Logic Gated CAR-NK cell therapy that can target a widely expressed tumor-associated antigen while protecting antigen-expressing healthy cells.

**CRC tumor and healthy tissue antigen pairing and validation** 

Senti Bio discovered and validated VSIG2 as a healthy tissue Safety Antigen to pair with the tumor-associated antigen CEA for the potential treatment of CRC.

### SITC 2021 Abstract #116

#### **Broad platform applicability**

This proof-of-concept shows that NOT GATE gene circuits can be used in NK cells to prevent target-mediated cytotoxicity in a Safety Antigen-dependent manner. NOT GATE gene circuits enable the possibility to target numerous tumor-associated antigens that have concerning expression in healthy tissues.